Celltrion enrolls COVID-19 patients in treatment trial

By The Science Advisory Board staff writers

November 25, 2020 -- Celltrion has enrolled patients with mild to moderate symptoms of SARS-CoV-2 infection in a phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment.

The company enrolled 327 people in the randomized, double-blind, placebo-controlled and parallel-group trial designed to evaluate the treatment's efficacy and safety. In addition, Celltrion plans to initiate a phase III clinical trial in more than 10 countries to obtain more safety and efficacy results of CT-P59.

The company expects to submit an emergency use authorization to the Korean Ministry of Food and Drug Safety once the results from the trial are revealed.

Celltrion is also working to increase its manufacturing capabilities to meet the need for anti-COVID-19 monoclonal antibody treatments. The company hopes to potentially deliver as many as 2 million doses of the treatment in 2021.

Copyright © 2020 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.